
Components of Other (income)/deductions––net include:
	Three Months Ended
(MILLIONS)		March 29, 2026		March 30, 2025
Interest income		$	(115)	$	(143)
Interest expense		668		654
Net interest expense		554		511
Net (gains)/losses recognized during the period on equity securities		9		370

Net periodic benefit costs/(credits) other than service costs		(72)		(158)
Certain legal matters, net(a)		191		142
Certain asset impairments(b)		—		224
Changes in fair value of contingent consideration liabilities(c)		295		8
Other, net		(116)		(144)
Other (income)/deductions––net		$	861	$	953

(a)The amount for the first quarter of 2026 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2025 included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.

(b)The amount for the first quarter of 2025 primarily represented an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.